Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 17 | 2025 | 623 | 3.100 |
Why?
|
| Ketamine | 13 | 2023 | 214 | 2.630 |
Why?
|
| Hallucinogens | 7 | 2025 | 41 | 2.430 |
Why?
|
| Depressive Disorder, Major | 9 | 2024 | 400 | 2.230 |
Why?
|
| Glutamic Acid | 4 | 2024 | 200 | 1.310 |
Why?
|
| Veterans | 9 | 2023 | 1738 | 1.110 |
Why?
|
| Ibogaine | 2 | 2023 | 2 | 1.100 |
Why?
|
| Stress, Psychological | 3 | 2020 | 555 | 1.000 |
Why?
|
| Antidepressive Agents | 11 | 2023 | 288 | 0.910 |
Why?
|
| Synaptic Transmission | 3 | 2020 | 348 | 0.830 |
Why?
|
| Nerve Net | 2 | 2020 | 238 | 0.690 |
Why?
|
| Laburnum | 1 | 2019 | 2 | 0.680 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 44 | 0.650 |
Why?
|
| Neurobiology | 2 | 2020 | 25 | 0.640 |
Why?
|
| Health Surveys | 1 | 2019 | 243 | 0.600 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 178 | 0.570 |
Why?
|
| Cognition | 2 | 2019 | 736 | 0.550 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 72 | 0.550 |
Why?
|
| Prefrontal Cortex | 5 | 2024 | 177 | 0.530 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 807 | 0.520 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 226 | 0.510 |
Why?
|
| Military Personnel | 3 | 2022 | 209 | 0.460 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2025 | 18 | 0.440 |
Why?
|
| Connectome | 3 | 2020 | 80 | 0.420 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2019 | 96 | 0.410 |
Why?
|
| Brain | 4 | 2023 | 2964 | 0.370 |
Why?
|
| Psychotherapy | 2 | 2025 | 224 | 0.360 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 2 | 2023 | 115 | 0.360 |
Why?
|
| Cerebral Cortex | 3 | 2018 | 448 | 0.340 |
Why?
|
| Suicide | 2 | 2023 | 175 | 0.330 |
Why?
|
| Humans | 35 | 2025 | 123280 | 0.300 |
Why?
|
| Suicidal Ideation | 3 | 2023 | 214 | 0.240 |
Why?
|
| Touch | 1 | 2025 | 34 | 0.240 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 162 | 0.220 |
Why?
|
| Methoxydimethyltryptamines | 1 | 2023 | 1 | 0.220 |
Why?
|
| Neurotransmitter Agents | 1 | 2024 | 145 | 0.220 |
Why?
|
| Mexico | 1 | 2023 | 179 | 0.210 |
Why?
|
| Sirolimus | 2 | 2022 | 220 | 0.210 |
Why?
|
| Adult | 13 | 2024 | 29091 | 0.200 |
Why?
|
| Glutamates | 2 | 2023 | 69 | 0.200 |
Why?
|
| Depression | 3 | 2023 | 1229 | 0.200 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 22 | 0.200 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 289 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2023 | 1389 | 0.190 |
Why?
|
| Combat Disorders | 1 | 2021 | 22 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 141 | 0.190 |
Why?
|
| Male | 16 | 2024 | 60345 | 0.190 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2024 | 174 | 0.180 |
Why?
|
| Mental Disorders | 2 | 2019 | 818 | 0.180 |
Why?
|
| Alcoholism | 1 | 2023 | 230 | 0.180 |
Why?
|
| Norepinephrine | 2 | 2018 | 174 | 0.160 |
Why?
|
| Neuroimaging | 2 | 2019 | 332 | 0.160 |
Why?
|
| Executive Function | 1 | 2019 | 106 | 0.150 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 22 | 0.150 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 62 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 65 | 0.150 |
Why?
|
| Middle Aged | 8 | 2024 | 26095 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 140 | 0.140 |
Why?
|
| Receptors, Glutamate | 1 | 2016 | 16 | 0.140 |
Why?
|
| Self Report | 1 | 2019 | 517 | 0.130 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 35 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 1171 | 0.130 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2015 | 36 | 0.120 |
Why?
|
| Female | 12 | 2024 | 65628 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2018 | 456 | 0.120 |
Why?
|
| Alleles | 1 | 2019 | 1601 | 0.120 |
Why?
|
| Amygdala | 1 | 2015 | 81 | 0.120 |
Why?
|
| Neural Pathways | 1 | 2016 | 265 | 0.120 |
Why?
|
| United States | 4 | 2025 | 10655 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 4692 | 0.100 |
Why?
|
| Cerebellum | 1 | 2016 | 415 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2023 | 6033 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2022 | 539 | 0.080 |
Why?
|
| Hippocampus | 1 | 2015 | 819 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3087 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 3553 | 0.080 |
Why?
|
| Emotions | 2 | 2023 | 361 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2022 | 1602 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 8870 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12176 | 0.060 |
Why?
|
| Harm Reduction | 1 | 2025 | 9 | 0.060 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2024 | 28 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 149 | 0.060 |
Why?
|
| Consciousness | 1 | 2024 | 49 | 0.050 |
Why?
|
| Spirituality | 1 | 2024 | 47 | 0.050 |
Why?
|
| Glutamine | 1 | 2024 | 207 | 0.050 |
Why?
|
| Psilocybin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 161 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 2955 | 0.040 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2020 | 16 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 664 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1497 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 113 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 263 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2023 | 857 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 131 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 132 | 0.040 |
Why?
|
| Arousal | 1 | 2016 | 81 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1690 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 679 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 98 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 220 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 577 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1081 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 803 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 396 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2844 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 774 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3558 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 365 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 19180 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 10033 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3384 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 33850 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 4225 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16081 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 19126 | 0.010 |
Why?
|